{"Clinical Trial ID": "NCT02447328", "Intervention": ["INTERVENTION 1:", "A single arm", "- Fulvestrant (Faslodex\u00ae)"], "Eligibility": ["Incorporation criteria:", "Women in post-menopausal situations", "* External or hospitalized patients with locally advanced or metastatic breast cancer who have failed with previous estrogen therapy.", "Positive estrogen receptor", "Radiographic progression of the disease after previous treatment", "Patients who agree to participate in this study and sign informed consent", "- Exclusion criteria:", "Patients treated with flulvestrant", "Patients treated with other antitumours", "Pregnant or lactating women", "History of hypersensitivity to any of the ingredients included (e.g. castor oil)", "Patients considered unfit for study by researchers", "Patients with severe liver or kidney dysfunction"], "Results": ["Performance measures:", "(Percentage of participants with side effects and/or side effects on medicines)", "Percentage of patients with ARs.", "Delay: Adverse reactions were collected from treatment initiation until the end of the study approximately 6 months for each patient.", "Results 1:", "Title of the arm/group: Single weapon", "Description of the arm/group: flulvestrant (Faslodex)", "Total number of participants analysed: 81", "Type of measurement: Number", "Unit of measure: Percentage of participants Adverse reactions (ARs): 81.5 (71.3 to 89.3)", "On the basis of the current South Korean label: 38.3 (27.7 to 49.7)", "AE serious: 11.1 (5.2 to 20.1)", "Serious ADR: 0 (0 to 4.4)", "Unforeseen EA: 71.6 (60.5-81.1)", "Unexpected ADR: 24.7 (15.8-35.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 9/81 (11.11 per cent)", "CHOLANGITIS 1/81 (1.23%)", "1/81 (1.23%)", "1/81 (1.23%)", "Increased blood creatinine 1/81 (1.23%)", "Bone pain 1/81 (1.23%)", "- Acute lymphocyte leukaemia (in remission) 1/81 (1.23%)", "1/81 (1.23%)", "Pelvic pain 1/81 (1.23%)"]}